JP2024518844A - Ｃ１ｓに結合する抗体およびその使用 - Google Patents

Ｃ１ｓに結合する抗体およびその使用 Download PDF

Info

Publication number
JP2024518844A
JP2024518844A JP2023571586A JP2023571586A JP2024518844A JP 2024518844 A JP2024518844 A JP 2024518844A JP 2023571586 A JP2023571586 A JP 2023571586A JP 2023571586 A JP2023571586 A JP 2023571586A JP 2024518844 A JP2024518844 A JP 2024518844A
Authority
JP
Japan
Prior art keywords
antibody
binding fragment
seq
fragment comprises
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518844A5 (enExample
Inventor
バヘ ベディアン，
Original Assignee
ダイアンサス セラピューティクス オプコ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアンサス セラピューティクス オプコ， インコーポレイテッド filed Critical ダイアンサス セラピューティクス オプコ， インコーポレイテッド
Publication of JP2024518844A publication Critical patent/JP2024518844A/ja
Publication of JP2024518844A5 publication Critical patent/JP2024518844A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023571586A 2021-05-20 2022-05-20 Ｃ１ｓに結合する抗体およびその使用 Pending JP2024518844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201952P 2021-05-20 2021-05-20
US63/201,952 2021-05-20
PCT/US2022/030189 WO2022246154A2 (en) 2021-05-20 2022-05-20 Antibodies that bind to c1s and uses thereof

Publications (2)

Publication Number Publication Date
JP2024518844A true JP2024518844A (ja) 2024-05-07
JP2024518844A5 JP2024518844A5 (enExample) 2025-05-28

Family

ID=84141843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571586A Pending JP2024518844A (ja) 2021-05-20 2022-05-20 Ｃ１ｓに結合する抗体およびその使用

Country Status (5)

Country Link
US (2) US12252550B2 (enExample)
EP (1) EP4340879A4 (enExample)
JP (1) JP2024518844A (enExample)
CN (1) CN117769434A (enExample)
WO (1) WO2022246154A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途
KR20250158063A (ko) 2023-03-16 2025-11-05 젠자임 코포레이션 건식 연령-관련 황반 변성의 치료
WO2025129535A1 (en) * 2023-12-20 2025-06-26 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
AU2024403267A1 (en) * 2023-12-20 2026-07-16 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
TW202547886A (zh) * 2024-02-02 2025-12-16 美商黛安瑟斯醫療運營公司 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法
US20250376511A1 (en) 2024-06-05 2025-12-11 Genzyme Corporation BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
WO2026076063A2 (en) * 2024-10-01 2026-04-09 Dianthus Therapeutics Opco, Inc. Compositions, doses, and methods for treatment of c1s mediated diseases and disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
SG10201900183VA (en) * 2011-04-28 2019-05-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
EP4212175A1 (en) * 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
TWI780083B (zh) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
EP4640703A3 (en) * 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use

Also Published As

Publication number Publication date
US20260022195A1 (en) 2026-01-22
US12252550B2 (en) 2025-03-18
WO2022246154A3 (en) 2023-01-12
EP4340879A4 (en) 2025-03-26
EP4340879A2 (en) 2024-03-27
US20220380483A1 (en) 2022-12-01
WO2022246154A2 (en) 2022-11-24
CN117769434A (zh) 2024-03-26

Similar Documents

Publication Publication Date Title
US12252550B2 (en) Antibodies that bind to C1S and uses thereof
JP2022180448A (ja) イヌ化抗体
ES2975006T3 (es) Anticuerpos humanos de alta afinidad contra el receptor humano de IL-4
US8357367B2 (en) Antibodies that bind PAR-2
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
US20240124590A1 (en) Pd1 binding agents
US12110344B2 (en) Antibodies that bind to cis and uses thereof
US12479920B2 (en) PD1 and VEGFR2 dual-binding agents
JP7675193B2 (ja) 血漿カリクレイン抗体及びその使用
JP2025084880A (ja) 共通軽鎖を含む抗体及びその使用
CA3091307A1 (en) Csf1r binding agents
KR101804988B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
HK40128682A (zh) 结合c1s的抗体和其用途
WO2023250415A2 (en) Antibodies against integrin alpha 11 beta 1 and uses thereof
HK1166509A1 (en) High affinity human antibodies to human protease-activated receptor-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260629